2024年9月4日 · Yonsa is used in combination with methylprednisolone to treat advanced prostate cancer because methylprednisolone helps to prevent the side effects of Yonsa caused by mineralocorticoid excess. Treatment with Yonsa can cause mineralocorticoid excess, which can result in side effects such as hypertension (high blood pressure), hypokalemia (low ...

2023年7月16日 · YONSA is a prescription medicine that is used along with methylprednisolone. YONSA is used to treat men with prostate cancer that has spread to other parts of the body and no longer responds to medical or surgical treatment that lowers testosterone. It is not known if YONSA is safe and effective in females or children.

2024年9月25日 · Yonsa (abiraterone acetate) from Sun Pharma is a unique, ultramicrosize (smaller particle size) formulation of the oral CYP17 inhibitor abiraterone acetate (approved as Zytiga). Sun Pharma's Yonsa is approved to be used in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

2025年1月6日 · For patients who develop hepatotoxicity during treatment with YONSA (ALT and/or AST greater than 5X ULN or total bilirubin greater than 3X ULN), interrupt treatment with YONSA. Treatment may be restarted at a reduced dose of 375 mg once daily following return of liver function tests to the patient’s baseline or to AST and ALT less than or ...

2024年11月1日 · Some dosage forms listed on this page may not apply specifically to the brand name Yonsa. Applies to abiraterone: oral tablet. Serious side effects of Yonsa. Along with its needed effects, abiraterone (the active ingredient contained in …

2024年12月23日 · Yonsa starts working quickly to lower testosterone levels in men with advanced prostate cancer, with averaged absolute testosterone levels falling to at or below 0.1 ng/dl by days 9 and 10 of treatment for 25 percent of men treated with Yonsa in the STAAR study.

2024年12月24日 · Yonsa is taken in combination with methylprednisolone. Yonsa is a CYP17 inhibitor that works by blocking the production of androgens used to make testosterone. Androgens are a group of hormones that includes testosterone, which play a key role in the development and function of the prostate gland.

2021年3月2日 · Yonsa (abiraterone acetate) is an ultramicrosize formulation of the oral CYP17 inhibitor abiraterone acetate (approved as Zytiga) used in combination with methylprednisolone for the treatment of metastatic castration-resistant prostate cancer.

2024年12月23日 · Yonsa works to prevent prostate cancer cells from growing and spreading by inhibiting the production of androgens, including testosterone. Androgens help prostate cancer cells grow and spread. Chemotherapy drugs work differently from hormone therapy drugs such as …

2018年5月22日 · Generic Yonsa Availability. Last updated on Jan 8, 2025. Yonsa is a brand name of abiraterone, approved by the FDA in the following formulation(s): YONSA (abiraterone acetate - tablet;oral) Manufacturer: SUN PHARM Approval date: May 22, 2018 Strength(s): 125MG ; Has a generic version of Yonsa been approved? No.